Impairment of the blood–brain barrier (BBB) integrity is implicated in the numerous
neurological disorders associated with neuroinflammation, neurodegeneration and aging. It …

In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

Cerebral endothelial cells and their linking tight junctions form a unique, dynamic and multi-
functional interface, the blood-brain barrier (BBB). The endothelium is regulated by …

The blood–brain barrier (BBB) is a highly regulated physical and functional boundary that
tightly controls the transport of materials between the blood and the brain. There is an …

Population aging that we are currently witnessing has led to an increase in chronic age-
related diseases, with dementia and depression being highlighted. Several studies establish …

Blood-brain barrier disruption occurs in the early stages of Alzheimer's disease. Recent
studies indicate a link between blood-brain barrier dysfunction and cognitive decline and …

The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery
of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely …

Neurodegenerative diseases are common, incurable neurological disorders with high
prevalence, and lead to memory, movement, language, and intelligence impairments …

The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two
unique central nervous system vasculature features that result in an intimate relationship …

Blood-brain barrier disruption plays an important role in central nervous system diseases.
This review provides information on the role of mitochondrial oxidative stress in brain …